AFAR has raised $35 million out of a needed $55 million for the Targeting Aging with Metformin Trial. There would still be the need for the NIH (National Institute of Health) to contribute another $40 million for the study.
Dr. Nir Barzilai, director of the Institute for Aging Research at the Albert Einstein College of Medicine, designed the Targeting Aging with Metformin anti-aging study. Metformin is an antidiabetic drug that was approved by the FDA more than 70 years ago. It is estimated that 120 million people take metformin. It has been shown to extend the lives of nematodes by 57% and mice by 6%.
TAME will consist of 3,000 patients between 65 – 79 years old and have a composite primary endpoint of myocardial infarction, stroke, heart failure, cancer, dementia and death. The trial could detect 22.5% reduced incidences of those diseases.
SOURCES- AFAR, New York Times, FDA, Nature
Written By Brian Wang, Nextbigfuture